Atezolizumab (Tecentriq) as first-line therapy in patients with metastatic urothelial carcinoma

Introduction . Nowadays the standard of care for locally advanced and metastatic urothelial carcinoma (UC) is a combination platinum-based drugs. However, such therapy characterized with high toxicity selective efficacy. So, question optimal alternative to first line choice drugs second currently relevant. Immune checkpoint inhibitors have revolutionized treatment UC. Nevertheless, despite fact that initially this series showed fairly efficacy as second-line UC, at present there no unambiguous opinion about correct tactics their use. There also consensus on predictive value PD-L1 biomarkers significance in determining tactics. Aim To evaluate tolerability first-line atezolizumab 22 patients unresectable forms Materials methods The experience State Clinical Hospital named after D.D. Pletnev example UC who received 1200 mg intravenously once every 21 days until progression or intolerable toxicity. Efficacy was assessed according RECIST 1.1 criteria. Results discussion Median follow-up 16.3 months. objective response rate (ORR) estimated 72.7%, 95% CI. A complete criteria observed 5 (22.7%). time 2.2 months (range 1.5-5.7), late responses (at 5.7 months) required space 2 patients. progression-free survival 5.2 (95% CI) all overall (OS) 18.5 CI). Specific application-related events were 10 (45.4%) cases. All side effects managed by symptomatic therapy. dosage atezoli-zumab reduced 7 (32%) Immune-mediated adverse reported (23%) No patient systemic non-corticosteroid immunomodulatory agents immune-mediated events. (9%) corticosteroids. Conclusions Atezolizumab has shown